Jazz Pharmaceuticals (JAZZ) Revenue (2010 - 2026)

Jazz Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• On a quarterly basis, Revenue rose 19.06% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $4.4 billion, a 9.2% increase from a year earlier, with the FY2025 full-year figure at $4.3 billion, up 4.88% from the prior year.
• Revenue fell to $1.1 billion in Q1 2026 per JAZZ's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Revenue topped out at $1.2 billion in Q4 2025 and bottomed at $813.7 million in Q1 2022.
• The 5-year median for Revenue is $972.1 million (2023), against an average of $994.1 million.
• Across the five-year window, Revenue jumped 33.93% in 2022 and decreased 0.46% in 2025, its largest moves.
• Year by year, Revenue stood at $972.1 million in 2022, then climbed by 4.1% to $1.0 billion in 2023, then grew by 7.53% to $1.1 billion in 2024, then advanced by 10.09% to $1.2 billion in 2025, then fell by 10.77% to $1.1 billion in 2026.
• Per Business Quant, the three latest JAZZ Revenue figures stand at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025).